Indian scientists develop novel drug delivery method to cut side effects of arthritis drug

Team Udayavani, Oct 26, 2020, 1:33 PM IST

New Delhi: Indian scientists have given a new lease of life to the arthritis medicine sulfapyridine by employing an innovative drug delivery method to remove its side effects.

Sulfapyridine is the third oldest drug still in use in the treatment of rheumatoid arthritis, an autoimmune inflammatory joint disease, according to the researchers from Lovely Professional University (LPU) in Punjab.

However, long term use of the drug results in side effects such as nausea or vomiting, rashes, dizziness, anxiety and abdominal pain, they said.

“As the molecule has side effect due to its higher dose, we developed a formulation which can be delivered directly to the site of action and thus is safe,” said Bhupinder Kapoor, Associate Professor, School of Pharmaceutical Sciences, LPU, told PTI.

In their study published in the peer-reviewed journal ‘Materials Science and Engineering C’, the researchers reported developing a prodrug of sulfapyridine and then incorporated it into an innovative delivery system.

The prodrug exhibited better retention in liposomes, as compared to the drug, thus reducing the symptoms of inflammation.

Liposomes are spherical vesicles having at least one lipid bilayer which are used as a vehicle for administration of pharmaceutical drugs.

The prodrug treatment is administered by injecting the affected area of the patient, and not through oral consumption, according to the researchers. This means that the medication only remains in the affected area, without spreading to the rest of the body, they said.

The research team, including Kapoor, Monica Gulati and Sachin K. Singh from LPU, successfully conducted the pre-clinical trials as well as the testing of the drug delivery mechanism.

“We conducted a study to understand the efficacy of sulfapyridine-derived liposomes. In arthritic rats, prodrug liposomes were found to reverse the symptoms of inflammation, including the levels of biochemical markers,” Kapoor explained.

“Therefore, liposomes of bio-responsive prodrugs offer a revolutionary approach in the treatment of rheumatoid arthritis,” he said.

The study was carried in collaboration with researchers at Fortis Hospital, Ludhiana & JSS College of Pharmacy, Ooty, Tamil Nadu.

The researchers said their prodrug will need approval for sales and marketing from India’s drug regulatory body.

The team has filed for a patent, and the pre-evaluation phase is now complete. They are also applying for an international patent for this new drug delivery method.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Pakistan issues visas to Indian pilgrims

‘Covid-19 vaccine for children soon’

Don’t leave high courts at state govts’ mercy for infrastructure funds, SC tells Centre

Kerala logs 5,405 new COVID-19 cases, 403 deaths

Kottiyoor rape case: Kerala HC commutes jail term of defrocked priest

We are getting best possible preparation for World Cup: Mithali

No material to show larger conspiracy in 2002 riots, idea is to keep “pot boiling”: SIT to SC

Related Articles More

Researchers try producing potato resistant to climate change

Space junk forces spacewalk delay, too risky for astronauts

Heart disease risk from saturated fats may depend on what foods they come from – new research

Indian-origin executive Parag Agrawal is new CEO of Twitter

First image of Omicron shows many more mutations than Delta


Barbados Becomes A Republic

NEWS BULLETIN 01-12-2021

Deadbody found at Bidirutala Forest Moodigere

Crocodile found at manvi river

Dandeli Clash between two groups

Latest Additions

Pakistan issues visas to Indian pilgrims

Maha: Man loses Rs 89,000 while ordering food online

‘Covid-19 vaccine for children soon’

Don’t leave high courts at state govts’ mercy for infrastructure funds, SC tells Centre

No incident of radioactive leakage from any nuclear power plant in India in last 3 years: Govt

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.